TY - JOUR
T1 - Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan
AU - Tseng, Chin Hsiao
AU - Huang, Yung-Kai
AU - Huang, Ya-Li
AU - Chung, Chi Jung
AU - Yang, Mo Hsiung
AU - Chen, Chien Jen
AU - Hsueh, Yu-Mei
N1 - Funding Information:
The study was supported by grants NSC-86-2314-B-038-038, NSC-87-2314-B-038-029, NSC-88-2314-B-038-112, NSC-88-2318-B-038-002-M51, NSC-89-2320-B-038-013, NSC-89-2318-B-038-M51, NSC-89-2314-B-038-049, NSC-90-2320-B-002-197, NSC-90-2320-B-038-021, NSC-91-3112-B-038-001, NSC-92-2320-B-002-156, NSC-92-3112-B-038-001, NSC-92-2321-B-038-004, and NSC-93-2320-B-002-071 from the National Science Council of the ROC.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2005/8/15
Y1 - 2005/8/15
N2 - Long-term exposure to ingested inorganic arsenic is associated with peripheral vascular disease (PVD) in the blackfoot disease (BFD)-hyperendemic area in Taiwan. This study further examined the interaction between arsenic exposure and urinary arsenic speciation on the risk of PVD. A total of 479 (220 men and 259 women) adults residing in the BFD-hyperendemic area were studied. Doppler ultrasound was used to diagnose PVD. Arsenic exposure was estimated by an index of cumulative arsenic exposure (CAE). Urinary levels of total arsenic, inorganic arsenite (AsIII) and arsenate (AsV), monomethylarsonic acid (MMAV), and dimethylarsinic acid (DMA V) were determined. Primary methylation index [PMI = MMA V/(AsIII + AsV)] and secondary methylation index (SMI = DMAV/MMAV) were calculated. The association between PVD and urinary arsenic parameters was evaluated with consideration of the interaction with CAE and the confounding effects of age, sex, body mass index, total cholesterol, triglycerides, cigarette smoking, and alcohol consumption. Results showed that aging was associated with a diminishing capacity to methylate inorganic arsenic and women possessed a more efficient arsenic methylation capacity than men did. PVD risk increased with a higher CAE and a lower capacity to methylate arsenic to DMAV. The multivariate-adjusted odds ratios for CAE of 0, 0.1-15.4, and >15.4 mg/L × year were 1.00, 3.41 (0.74-15.78), and 4.62 (0.96-22.21), respectively (P <0.05, trend test); and for PMI ≤ 1.77 and SMI > 6.93, PMI > 1.77 and SMI > 6.93, PMI > 1.77 and SMI ≤ 6.93, and PMI ≤ 1.77 and SMI ≤ 6.93 were 1.00, 2.93 (0.90-9.52), 2.85 (1.05-7.73), and 3.60 (1.12-11.56), respectively (P <0.05, trend test). It was concluded that individuals with a higher arsenic exposure and a lower capacity to methylate inorganic arsenic to DMAV have a higher risk of developing PVD in the BFD-hyperendemic area in Taiwan.
AB - Long-term exposure to ingested inorganic arsenic is associated with peripheral vascular disease (PVD) in the blackfoot disease (BFD)-hyperendemic area in Taiwan. This study further examined the interaction between arsenic exposure and urinary arsenic speciation on the risk of PVD. A total of 479 (220 men and 259 women) adults residing in the BFD-hyperendemic area were studied. Doppler ultrasound was used to diagnose PVD. Arsenic exposure was estimated by an index of cumulative arsenic exposure (CAE). Urinary levels of total arsenic, inorganic arsenite (AsIII) and arsenate (AsV), monomethylarsonic acid (MMAV), and dimethylarsinic acid (DMA V) were determined. Primary methylation index [PMI = MMA V/(AsIII + AsV)] and secondary methylation index (SMI = DMAV/MMAV) were calculated. The association between PVD and urinary arsenic parameters was evaluated with consideration of the interaction with CAE and the confounding effects of age, sex, body mass index, total cholesterol, triglycerides, cigarette smoking, and alcohol consumption. Results showed that aging was associated with a diminishing capacity to methylate inorganic arsenic and women possessed a more efficient arsenic methylation capacity than men did. PVD risk increased with a higher CAE and a lower capacity to methylate arsenic to DMAV. The multivariate-adjusted odds ratios for CAE of 0, 0.1-15.4, and >15.4 mg/L × year were 1.00, 3.41 (0.74-15.78), and 4.62 (0.96-22.21), respectively (P <0.05, trend test); and for PMI ≤ 1.77 and SMI > 6.93, PMI > 1.77 and SMI > 6.93, PMI > 1.77 and SMI ≤ 6.93, and PMI ≤ 1.77 and SMI ≤ 6.93 were 1.00, 2.93 (0.90-9.52), 2.85 (1.05-7.73), and 3.60 (1.12-11.56), respectively (P <0.05, trend test). It was concluded that individuals with a higher arsenic exposure and a lower capacity to methylate inorganic arsenic to DMAV have a higher risk of developing PVD in the BFD-hyperendemic area in Taiwan.
KW - Arsenic exposure
KW - Peripheral vascular disease
KW - Urinary arsenic speciation
UR - http://www.scopus.com/inward/record.url?scp=22544460259&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22544460259&partnerID=8YFLogxK
U2 - 10.1016/j.taap.2004.11.022
DO - 10.1016/j.taap.2004.11.022
M3 - Article
C2 - 16039941
AN - SCOPUS:22544460259
VL - 206
SP - 299
EP - 308
JO - Toxicology and Applied Pharmacology
JF - Toxicology and Applied Pharmacology
SN - 0041-008X
IS - 3
ER -